Miguel Zugman, Medical Oncologist at Einstein Hospital Israelita, shared on X:
“Our editorial in ESMO Open builds on the meta-analysis by Chiara Ciccarese et al. to examine the trade-offs of adding systemic immune checkpoint inhibitors to intravesical BCG in high-risk NMIBC.”
You can also read:
BOND-003 Phase 3: Cretostimogene Shows 75% Complete Response Rate in BCG-Unresponsive NMIBC
